Logo

Qiagen, Abbott Expand Alliance to Include Artus Infectious Disease Assays

Jun 23, 2005

NEW YORK, June 23 (GenomeWeb News) - Qiagen and Abbott have extended an existing distribution agreement, the companies said yesterday.

 

Terms of the original agreement gave Abbott distribution rights to an undisclosed number of real-time PCR diagnostic tests for use on Applied Biosystems detection instruments. The PCR assays were developed by Artus, a company Qiagen recently acquired.


Under the extended agreement, Abbott will have non-exclusive distribution rights to certain other Qiagen products, including infectious disease tests for hepatitis B, Epstein-Barr virus, Varicella-Zoster virus, Parvo B19 virus, cytomegalovirus, herpes simplex virus, and enterovirus. These products "complement" tests developed and manufactured by Abbott and Celera Diagnostics, Qiagen said in a statement.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.